Moving Towards Precision Therapy for Patients with AML: Clinical Challenges and Future Directions

In this clinic-focused program, review current and emerging strategies for personalizing AML treatment with expert-authored commentaries, and an on-demand Webcast capturing expert discussion from the 2018 hematologic malignancies symposium in San Diego. Then download the meeting slidesets and decision support resources on prognostic factors and key AML clinical trials to help guide your AML treatment recommendations.

Farhad Ravandi, MD
Program Director
Stéphane de Botton, MD
Mark J. Levis, MD, PhD
Farhad Ravandi, MD
Gary J. Schiller, MD
Eunice S. Wang, MD

ClinicalThought

New targeted agents are improving outcomes in newly diagnosed and relapsed/refractory AML. How can we optimize our diagnostic and treatment approaches for patients based on karyotype, FLT3 status, and other biomarkers?

Eunice S. Wang, MD Released: September 12, 2018

New drugs and drug combinations, particularly targeted therapies, are changing the treatment paradigm for patients with newly diagnosed and relapsed/refractory AML.

Farhad Ravandi, MD Released: October 15, 2018

At ASH 2018, exciting new data were presented on targeted therapy–based regimens for patients with newly diagnosed AML or unfit for conventional chemotherapy along with data on novel immunotherapies.

Gary J. Schiller, MD Released: December 27, 2018

On-Demand Webcast

Watch this on-demand Webcast from the CCO AML satellite symposium at ASH 2018, featuring expert faculty Stéphane de Botton, MD, PhD, Mark J. Levis, MD, PhD, Farhad Ravandi, MD, Gary J. Schiller, MD, and Eunice S. Wang, MD, as they present the latest clinical advances in treatment strategies for patients with AML, including newly approved agents.

Farhad Ravandi, MD
Program Director
Stéphane de Botton, MD Mark J. Levis, MD, PhD Gary J. Schiller, MD Eunice S. Wang, MD
Physicians: maximum of 2.25 AMA PRA Category 1 Credits Released: February 7, 2019 Expiration: February 6, 2020

AML Resource Guides

Download and use this handy reference guide to review currently recruiting phase III clinical trials in acute myeloid leukemia for your patients with AML.

Farhad Ravandi, MD
Program Director
Released: November 28, 2018

Download and use this handy reference to help guide the use of prognostic factors in treatment decisions for your patients with acute myeloid leukemia (AML).

Released: November 27, 2018

Downloadable Slideset

Download this slideset from a live ASH symposium reviewing the current and future management of acute myeloid leukemia (AML) using antibody-based therapies including antibody-drug conjugates.

Farhad Ravandi, MD
Program Director
Released: December 4, 2018

Download this slideset from a live ASH symposium reviewing the challenges and treatment options, including recently approved agents, for patients with newly diagnosed acute myeloid leukemia (AML).

Gary J. Schiller, MD Released: December 5, 2018

Download this slideset from a live ASH symposium reviewing the latest treatment approaches, including newly approved agents, for patients with FLT3-mutated AML.

Mark J. Levis, MD, PhD Released: December 4, 2018

Download this slideset from a live ASH symposium reviewing the latest treatment approaches, including newly approved agents, for patients with IDH-mutated AML.

Stéphane de Botton, MD Released: December 5, 2018

Download this slideset from a live ASH symposium reviewing newly approved and investigational agents for AML.

Eunice S. Wang, MD Released: December 5, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by educational grants from
Actinium
Astellas
Boston Biomedical
Celgene Corporation
Daiichi Sankyo
Jazz Pharmaceuticals
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?